Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Matthew R Smith

Showing results (81-90 of 319) with videos related to

Pageof 32
Sort By:
Psycho-Oncology|April 20, 2007
Prospective study of depression and fatigue in men with advanced prostate cancer receiving hormone therapyWilliam F Pirl, Joseph A Greer, Melissa Goode, et al.
Urology|March 1, 2008
Adipocytokines, obesity, and insulin resistance during combined androgen blockade for prostate cancerMatthew R Smith, Hang Lee, Mary Anne Fallon, et al.
The Journal of Clinical Endocrinology and Metabolism|August 5, 2004
Raloxifene to prevent gonadotropin-releasing hormone agonist-induced bone loss in men with prostate cancer: a randomized controlled trialMatthew R Smith, Mary Anne Fallon, Hang Lee, et al.
Drugs|February 16, 2011
Gonadotropin-releasing hormone agonists and the risks of type 2 diabetes and cardiovascular disease in men with prostate cancerPhilip J Saylor, Nancy L Keating, Stephen J Freedland, et al.
The New England Journal of Medicine|May 27, 2011
Case records of the Massachusetts General Hospital. Case 16-2011. A 67-year-old man with recurrent prostate cancerMatthew R Smith, Anthony L Zietman, Joel S Finkelstein, et al.
European Urology|April 28, 2012
Does comorbidity influence the risk of myocardial infarction or diabetes during androgen-deprivation therapy for prostate cancer?Nancy L Keating, A James O'Malley, Stephen J Freedland, et al.
Journal of the Air & Waste Management Association (1995)|January 7, 2017
Population Density, Particulate Emission Characterization, and Impact on the Particulate Inventory of Smoking Vehicles in the South Coast Air Quality Management DistrictThomas D Durbin, Matthew R Smith, Joseph M Norbeck, et al.
Psycho-Oncology|December 12, 2002
Depression in men receiving androgen deprivation therapy for prostate cancer: a pilot studyWilliam F Pirl, Gabrielle I Siegel, Melissa J Goode, et al.
European Urology|February 23, 2013
Androgen-deprivation therapy and risk for biliary disease in men with prostate cancerPhilip J Saylor, Matthew R Smith, A James O'Malley, et al.
Journal of the National Cancer Institute|December 5, 2012
Diabetes and cardiovascular disease during androgen deprivation therapy: observational study of veterans with prostate cancerNancy L Keating, A James O'Malley, Stephen J Freedland, et al.
Pageof 32

Showing results (81-90 of 319) with videos related to

Sort By:
Pageof 32
Psycho-Oncology|April 20, 2007
Prospective study of depression and fatigue in men with advanced prostate cancer receiving hormone therapyWilliam F Pirl, Joseph A Greer, Melissa Goode, et al.
Urology|March 1, 2008
Adipocytokines, obesity, and insulin resistance during combined androgen blockade for prostate cancerMatthew R Smith, Hang Lee, Mary Anne Fallon, et al.
The Journal of Clinical Endocrinology and Metabolism|August 5, 2004
Raloxifene to prevent gonadotropin-releasing hormone agonist-induced bone loss in men with prostate cancer: a randomized controlled trialMatthew R Smith, Mary Anne Fallon, Hang Lee, et al.
Drugs|February 16, 2011
Gonadotropin-releasing hormone agonists and the risks of type 2 diabetes and cardiovascular disease in men with prostate cancerPhilip J Saylor, Nancy L Keating, Stephen J Freedland, et al.
The New England Journal of Medicine|May 27, 2011
Case records of the Massachusetts General Hospital. Case 16-2011. A 67-year-old man with recurrent prostate cancerMatthew R Smith, Anthony L Zietman, Joel S Finkelstein, et al.
European Urology|April 28, 2012
Does comorbidity influence the risk of myocardial infarction or diabetes during androgen-deprivation therapy for prostate cancer?Nancy L Keating, A James O'Malley, Stephen J Freedland, et al.
Journal of the Air & Waste Management Association (1995)|January 7, 2017
Population Density, Particulate Emission Characterization, and Impact on the Particulate Inventory of Smoking Vehicles in the South Coast Air Quality Management DistrictThomas D Durbin, Matthew R Smith, Joseph M Norbeck, et al.
Psycho-Oncology|December 12, 2002
Depression in men receiving androgen deprivation therapy for prostate cancer: a pilot studyWilliam F Pirl, Gabrielle I Siegel, Melissa J Goode, et al.
European Urology|February 23, 2013
Androgen-deprivation therapy and risk for biliary disease in men with prostate cancerPhilip J Saylor, Matthew R Smith, A James O'Malley, et al.
Journal of the National Cancer Institute|December 5, 2012
Diabetes and cardiovascular disease during androgen deprivation therapy: observational study of veterans with prostate cancerNancy L Keating, A James O'Malley, Stephen J Freedland, et al.
Pageof 32